Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serlopitant in chronic pruritus of unknown origin
NCT03841331Phase 2Completed
- Sponsor
- Vyne Therapeutics
- Start
- Jan 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic pruritus of unknown origin (CPUO) comparing Serlopitant 5 mg with Placebo (2 arms). Primary endpoints: Worst Itch Numeric Rating Scale 4-point Responder Rate at 10 weeks, Change From Baseline in WI-NRS at 10 weeks and 2 more. Started Jan 2019; status: completed.
02
Drugs
serlopitant
03
Conditions
chronic pruritus of unknown origin (CPUO)
Beyond the preview
Go deeper on NCT03841331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03841331.